Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide or CC-99282 in Combination With R-CHOP-21 or Polatuzumab-R-CHP in Previously Untreated Aggressive B-cell Lymphoma
NCT04884035Phase 1Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Sep 2021
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, randomised, open-label trial of iberdomide and golcadomide in aggressive B-cell lymphoma (4 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 1 more. Started Sep 2021; status: active, not recruiting.
02
Drugs
iberdomidegolcadomide
03
Conditions
aggressive B-cell lymphoma
Beyond the preview
Go deeper on NCT04884035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04884035.